IRB #

IRB00011848

Title

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence

Principal Investigator

Anna Bar

Study Purpose

In this study the study sponsor, Polynoma LLC, is testing a cancer vaccine called Seviprotimut-L, to determine its safety and effectiveness in delaying the recurrence of melanoma.

Medical Condition(s)

The condition being studied is melanoma of the skin.

Eligibility Criteria

To be eligible for this study you must have had a confirmed stage IIB, IIC, or III melanoma that has been surgically removed and be 18 years of age or older.

Age Range

18 - 80

Healthy Volunteers Needed

No

Duration of Participation

This study will take 15 clinic visits and 2 years to complete.

Minors Included

No

Contact

call Liz Stoos at 503-418-9386 or e-mail dermtrials@ohsu.edu

Sponsor

Polynoma LLC
11230 Sorrento Valley Road, Suite 215
San Diego, CA 92121

Recruitment End

12/06/2017

Compensation Provided

No


Go Back